Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2023 07:15 ET | Source: Assertio Holdings, Inc.

Assertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 Outlook

Net Product Sales Increase 18% Year-Over-Year Raises Full Year Outlook to Net Product Sales of $157 to $167 Million, Adjusted EBITDA $90 to $98 Million To Acquire Spectrum...
May 05, 2023 08:00 ET | Source: Assertio Holdings, Inc.

Assertio Holdings, Inc. Updates First Quarter 2023 Financial Results Call Time to Tuesday, May 9, 2023 at 11:30 am Eastern Time

LAKE FOREST, Ill., May 05, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
April 27, 2023 09:00 ET | Source: Assertio Holdings, Inc.

Assertio Holdings, Inc. to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023

LAKE FOREST, Ill., April 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
April 25, 2023 06:00 ET | Source: Assertio Holdings, Inc.; Spectrum Pharmaceuticals, Inc.

Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction

Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio’s Omni-Channel...
April 24, 2023 09:00 ET | Source: Assertio Holdings, Inc.

Assertio Provides Educational Grant for New Lennox-Gastaut Syndrome (LGS) Foundation Treatments Kits

SYMPAZAN (clobazam) oral CIV film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and older Oral film delivery from SYMPAZAN® delivers...
April 07, 2023 16:00 ET | Source: Assertio Holdings, Inc.

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LAKE FOREST, Ill., April 07, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to...
March 08, 2023 16:01 ET | Source: Assertio Holdings, Inc.

Assertio Reports Fourth Quarter and Full Year 2022 Financial Results

Net Product Sales Increase 55% in the Fourth Quarter, 42% for the Full Year Full Year Net Income Increases to $109.6 Million, Non-GAAP Adjusted EBITDA Increases to $101.6 Million Cash Flows from...
March 06, 2023 09:00 ET | Source: Assertio Holdings, Inc.

Assertio Appoints Dr. Howard Franklin as Senior Vice President, Medical

LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
February 23, 2023 07:14 ET | Source: Assertio Holdings, Inc.

Assertio Announces Exchange Offer of $30 Million of its Currently Outstanding 6.50% Convertible Senior Notes Due 2027

LAKE FOREST, Ill., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today...
February 21, 2023 07:00 ET | Source: Assertio Holdings, Inc.

Assertio Holdings, Inc. Announces Preliminary Fourth Quarter and Full Year 2022 Results

Year-over-Year Net Product Sales Increased at Least 54% for the Fourth Quarter and 41% for the Full Year Cash Flows from Operations Was at Least $26 Million for the Fourth Quarter and $78 Million for...